Virus-mediated gene transfer to induce therapeutic angiogenesis: where do we stand?
The potential to induce therapeutic angiogenesis through gene transfer has engendered much excitement as a possible treatment for tissue ischemia. After 10 years of clinical experimentation, however, it now appears clear that several crucial issues are still to be resolved prior to achieving clinical success. These include the understanding of whether functional blood vessels might arise as a result of the delivery of a single angiogenic factor or require more complex cytokine combinations, the identification of the proper timing of therapeutic gene expression and, most notably, the development of more efficacious gene delivery tools. Viral vectors based on the adeno-associated virus (AAV) appear particularly suitable to address the last requirement, since they display a specific tropism for skeletal muscle cells and cardiomyocytes, and drive expression of the therapeutic genes in these cells for indefinite periods of time. In this review, I discuss the current applications of gene therapy for cardiovascular disorders, with particular attention to the possible improvements in the technologies involved in virus-mediated gene transfer.
Giacca
Mauro
M
Molecular Medicine Laboratory, International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano 99,Trieste, Italy. giacca@icgeb.org
D000256:Adenoviridae / Q000235:genetics*; D043925:Angiogenesis Inducing Agents / Q000008:administration & dosage*; D000818:Animals; D004279:DNA, Viral / Q000008:administration & dosage* / Q000235:genetics; D018014:Gene Transfer Techniques / Q000639:trends*; D015316:Genetic Therapy / Q000639:trends*; D005822:Genetic Vectors / Q000235:genetics; D006801:Humans; D018919:Neovascularization, Physiologic / Q000187:drug effects / Q000235:genetics*; D014162:Transfection / Q000639:trends*
D043925:Angiogenesis Inducing Agents; D004279:DNA, Viral